FerroptoCure is a research firm that specializes in ferroptosis research and the development of therapeutic drugs to treat diseases.
FerroptoCure has raised $3.1M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
FerroptoCure's investors include ANRI, TUSIC, Japan Science and Technology Agency, AMED, Diamond Medino Capital.
FerroptoCure is headquartered in Tokyo, Japan.
FerroptoCure is a research firm that specializes in ferroptosis research and the development of therapeutic drugs to treat diseases.
FerroptoCure is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"FerroptoCure — Funding & Investors." VCBacked, September 19, 2025, https://www.vcbacked.co/company/ferroptocure. Accessed August 14, 2026.
VCBacked. (2025). FerroptoCure — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/ferroptocure
{{cite web |title=FerroptoCure — Funding & Investors |url=https://www.vcbacked.co/company/ferroptocure |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated